Simplify Medical closed a US $21.0MM Series B financing. Funds will support two ongoing U.S. pivotal clinical trials of the Simplify cervical disc.
Ongoing studies include:
- a two-level, prospective pivotal trial of up to 200 patients at up to 15 centers
- a pivotal trial comparing one-level cervical implantation of the device with cervical fusion surgery from a historical nonconcurrent control group
Life Sciences Partners led the round, with additional investment from Sectoral Asset Management and existing investor M.H. Carnegie.
Simplify Disc has received CE Mark approval and has been used to treat >700 patients ex-U.S. over the last three years.
Sources: Simplify Medical; ORTHOWORLD Inc.
Simplify Medical closed a US $21.0MM Series B financing. Funds will support two ongoing U.S. pivotal clinical trials of the Simplify cervical disc.
Ongoing studies include:
a two-level, prospective pivotal trial of up to 200 patients at up to 15 centers
a pivotal trial comparing one-level cervical implantation of the...
Simplify Medical closed a US $21.0MM Series B financing. Funds will support two ongoing U.S. pivotal clinical trials of the Simplify cervical disc.
Ongoing studies include:
- a two-level, prospective pivotal trial of up to 200 patients at up to 15 centers
- a pivotal trial comparing one-level cervical implantation of the device with cervical fusion surgery from a historical nonconcurrent control group
Life Sciences Partners led the round, with additional investment from Sectoral Asset Management and existing investor M.H. Carnegie.
Simplify Disc has received CE Mark approval and has been used to treat >700 patients ex-U.S. over the last three years.
Sources: Simplify Medical; ORTHOWORLD Inc.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
